Target intelligence / Profile preview

SPANXA2 overlapping transcript 1 (SPANXA2-OT1)

Target
SPANXA2-OT1
Molecular classification
Long non-coding RNA (lncRNA), Other
01

Overview

SPANXA2 overlapping transcript 1 (SPANXA2-OT1) is a long non-coding RNA (lncRNA) that is significantly upregulated in specific types of kidney injury, particularly crystalline nephropathy caused by calcium oxalate crystals. Experimental evidence shows it regulates the occurrence and development of epithelial-mesenchymal transition (EMT) in renal tubular epithelial cells by acting as a molecular sponge for miR-204, which in turn modulates the expression of Smad5. Through this axis, SPANXA2-OT1 promotes EMT, inhibits cell proliferation, and promotes apoptosis in renal epithelial cells. Additionally, it may influence chemokine expression and macrophage chemotaxis, suggesting a broader immunoregulatory role. Its dysregulation has also been noted in non-functioning pituitary adenomas and cancers, indicating possible wider relevance in oncology, but it is not characterized as a therapeutic target such as a receptor, enzyme, or transporter[1][3][4].

Other names
SPANXA2-OT1CXorf18FLJ36186SPANXA2 overlapping transcript 1 (non-protein coding)Putative uncharacterized protein SPANXA2-OT1
02

Biological functions

Regulation of epithelial-mesenchymal transition (EMT)Modulation of cell proliferationPromotion of cell apoptosisRegulation of chemokine expression and macrophage chemotaxis
03

Disease associations

Kidney injury/fibrosis (particularly crystalline nephropathy)Potential involvement in cancer and pituitary adenoma (based on differential expression in cancer datasets)

Beyond the preview

Go deeper on SPANXA2 overlapping transcript 1 (SPANXA2-OT1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPANXA2 overlapping transcript 1 (SPANXA2-OT1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call